FDA ap­proves As­traZeneca’s asth­ma med­ica­tion Fasen­ra to treat rare au­toim­mune con­di­tion

A few months af­ter a key la­bel ex­pan­sion, As­traZeneca’s asth­ma treat­ment Fasen­ra has re­ceived FDA ap­proval to treat a rare in­flam­ma­to­ry dis­ease.

The com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER